Dr. Kamala Ley-Thriemer
Clinical trials coordinator
PhD, University Antwerp, Belgium, 2013; Master of Public Health, University Liverpool, UK, 2011; Medical degree, Medical University Vienna, Austria, 2005
Approved level of HDR supervision at Charles Darwin University:
Associate Supervisor for PhD
Kamala Ley-Thriemer joined Menzies School of Health Research at the beginning of 2014 as the clinical trials coordinator for several malaria studies.
Kamala graduated from the Medical University Vienna (MUV), Austria in 2005 where she first began researching antimalarial drug resistance in Thailand and Bangladesh. Kamala graduated with a Master of Public Health from the University of Liverpool in 2011, and recently received her PhD degree from the University Antwerp, Belgium with her thesis on Typhoid Fever.
She has lived and worked in the field in both Asia and throughout Africa for the last eight years focusing on malaria, typhoid and cholera. She has expertise in vaccine trials, therapeutic trials and epidemiological studies.
Most recently, Kamala was a clinical researcher and medical epidemiologist at the Clinical Science Department of Institute for Tropical Medicine (ITM), Antwerp, where she was responsible for the support of several clinical malaria trials in Africa and Asia.
In 2019, Kamala was awarded a CSL Centenary Fellowship to develop and optimise treatment programs against vivax malaria in SE Asia and the Horn of Africa. The Fellowship will allow Kamala to generate country-specific roadmaps to guide public health programs.
- Optimizing the radical cure of P.vivax malaria (OPRA)
- ACROSS Study: Populations at risk of malaria and drug induced haemolysis
- PRIMA clinical trial: Universal Radical Cure of P. vivax malaria
- SIRIN clinical trial: Radical cure of P. vivax malaria in Nepal
- IMPROV Study: Short-course treatment regimen for radical cure of P. vivax malaria
- Asia Pacific Malaria elimination network (APMEN).
- Wangchuk, S., Drukpa, T., Penjor, K., Peldon, T., Dorjey, Y., Dorji, K., et al. (2016). Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malaria Journal,15(1), 277. doi: 10.1186/s12936-016-1320-8.
- PREGACT Study Group, Pekyi D, Ampromfi AA, Tinto H, Traoré-Coulibaly M, Tahita MC, Valéa I, Mwapasa V, Kalilani-Phiri L, Kalanda G, Madanitsa M, Ravinetto R, Mutabingwa T, Gbekor P, Tagbor H, Antwi G, Menten J, De Crop M, Claeys Y, Schurmans C, Van Overmeir C, Thriemer K, Van Geertruyden JP, D'Alessandro U, Nambozi M, Mulenga M, Hachizovu S, Kabuya JB, Mulenga J. (2016). Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 374(10), 913-27. doi: 10.1056/NEJMoa1508606.
- Tobgay, T., Samdrup, P., Jamtsho, T., Mannion, K., Ortega, L., Khamsiriwatchara, A., et al. (2016). Performance and user acceptance of the Bhutan Febrile & Malaria Information System (BFMIS): report from a pilot study. Malaria Journal, 15,52 doi:10.1186/s12936-016-1105-0
- Getachew, S., Thriemer, K., Auburn, S., Abera, A., Gadisa, E., Aseffa, A., et al. (2015). Chloroquine efficacy for Plasmodium vivax malaria in Southern Ethiopia. Malaria Journal, 14(1), 525. doi: 10.1186/s12936-015-1041-4.
- The IMPROV study group.(2015). Improving the radical cure of vivax malaria (IMPROV): A study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infectious Diseases, 15,558. doi: 10.1186/s12879-015-1276-2.
- The APMEN Vivax Working Group. (2015). Targeting vivax malaria in the Asia Pacific - The Asia Pacific malaria elimination network vivax working group. Malaria Journal, 14, 484. doi: 10.1186/s12936-015-0958-y
- Thriemer, K., Hong, N.V., Rosanas-Urgell, A., Phuc, B.Q., Ha, D.M., Pockele, E., et al. (2014). Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 58(12), 7049-55. pii: AAC.02746-14.
- Thriemer, K., Ley, B., Menten, J.,& van den Ende, J.(2013). A systematic review and meta-analyses of the performance of two point of care typhoid fever tests, Tubex TF and Typhid,ot, in endemic countries. PLoS One, 8(12) e81263. doi: 10.1371/journal.pone.0081263.
- Thriemer, K., Ley, B., Ame, S., Deen, J., Pak, G.D., Chang, N.Y., et al. Clinical and Epidemiological Features of Typhoid Fever in Pemba, Zanzibar: Assessment of the WHO case definition. PLoS ONE, 7(12): e51823. doi:10.1371/journal.pone.0051823
- Thriemer, K., Ley, B., Ame, S., von Seidlein, L., Pak,G.D., Chang, N.Y., et al. (2012). The burden of invasive bacterial infections in Pemba, Zanzibar. PLoS One,7(2), e30350
Menzies School of Health (Menzies) researcher Dr Kamala Thriemer has been awarded a prestigious $1.25 million CSL Centenary Fellowship to develop and optimise treatment programs against vivax malaria in SE Asia and the Horn of Africa.
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.
A new research study has shown that a seven-day treatment with a high dose of an anti-malaria drug can be tolerated by patients
A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated.
MESA Correspondents bring you cutting-edge coverage from the 7th International Conference on Plasmodium vivax Research (ICPVR 2019).
Wrapping up the 7th International Conference on Plasmodium vivax Research, day three focused on the topics of P. vivax drugs and approaches for P. vivax elimination.
The largest grant, of $257,767, goes to the Menzies School of Health Research for a project with collaborators in Bangladesh, Indonesia and the Netherlands.
Among the other projects funded are the Menzies School of Health Research partnering with Bangladesh, Indonesia and Nepal to develop malaria treatments.
A study led by the Menzies School of Health Research recommends a two-stage treatment for the notoriously difficult-to-cure Plasmodium vivax malaria
A study into the treatment of the difficult-to-cure Plasmodium vivax malaria in Ethiopia.